P2, N=24, Not yet recruiting, Universiti Kebangsaan Malaysia Medical Centre | Initiation date: Jul 2025 --> Feb 2026

P=N/A, N=32, Not yet recruiting, Xiangya Hospital, Central South University; Xiangya Hospital, Central South University

P=N/A, N=28, Recruiting, University Hospital, Basel, Switzerland

P4, N=111, Active, not recruiting, University of California, Irvine | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2027 --> Jun 2027

P2, N=36, Recruiting, Dartmouth-Hitchcock Medical Center | Trial primary completion date: May 2026 --> May 2027

P3, N=58, Completed, University of Southern California | Suspended --> Completed

EA of SP4 can regulate the level of serum sex hormones, slow down the aging process of ovarian granulosa cells, improve the ovarian reserve function and fertility of POI rats, which may be related to its function in regulating P53/P21 signaling pathway.

P4, N=124, Completed, University of Illinois at Chicago | N=90 --> 124

P=N/A, N=52, Completed, University Hospital, Lille | Active, not recruiting --> Completed

P4, N=80, Recruiting, University of Delaware | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Apr 2025 --> Dec 2025

Here, we performed a synthetic lethal drug screening in an approved drug library with ARID1A isogenic CRC cell lines and identified estramustine phosphate sodium (EMP), an FDA approved antimicrotubule chemotherapy drug, as a synthetic lethal partner of ARID1A...Furthermore, we identified that MAP4 is phosphorylated by PI3K, which is activated by ARID1A loss. These findings highlight MAP4 as a key regulator of microtubule dynamics in ARID1A-deficient cells and unveil a novel synthetic lethality relationship between ARID1A and EMP.